This study was terminated in the United States, in France, in Estonia, .... It is testing brexpiprazole for PTSD.
PTSDDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Brexpiprazole as Adjunctive Treatment may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive Brexpiprazole as Adjunctive Treatment, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Estonia, in Finland, and in France.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateDecember 2013
Recruitment status
Terminated
Enrollment listed in the registry
417
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Estonia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01987960
Official title
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01987960. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Estonia · 1 site
EE001
Tallinn
Site status: Not listed — confirm with the team
Finland · 6 sites
FI002
Helsinki
Site status: Not listed — confirm with the team
FI003
Helsinki
Site status: Not listed — confirm with the team
FI001
Kuopio
Site status: Not listed — confirm with the team
FI006
Oulu
Site status: Not listed — confirm with the team
FI005
Tampere
Site status: Not listed — confirm with the team
FI004
Turku
Site status: Not listed — confirm with the team
France · 5 sites
FR002
Fort de France
Site status: Not listed — confirm with the team
FR003
Laxou
Site status: Not listed — confirm with the team
FR004
Nîmes
Site status: Not listed — confirm with the team
FR005
Thuir
Site status: Not listed — confirm with the team
FR001
Tours
Site status: Not listed — confirm with the team
Italy · 5 sites
IT005
Andria
Site status: Not listed — confirm with the team
IT004
Catania
Site status: Not listed — confirm with the team
IT003
Lecce
Site status: Not listed — confirm with the team
IT001
Pisa
Site status: Not listed — confirm with the team
IT002
Siena
Site status: Not listed — confirm with the team
Poland · 5 sites
PL003
Bialystok
Site status: Not listed — confirm with the team
PL004
Gdansk
Site status: Not listed — confirm with the team
PL005
Gdansk
Site status: Not listed — confirm with the team
PL001
Leszno
Site status: Not listed — confirm with the team
PL002
Lublin
Site status: Not listed — confirm with the team
Serbia · 3 sites
RS006
Belgrade
Site status: Not listed — confirm with the team
RS004
Niš
Site status: Not listed — confirm with the team
RS005
Novi Kneževac
Site status: Not listed — confirm with the team
South Africa · 9 sites
ZA006
Bloemfontein
Site status: Not listed — confirm with the team
ZA002
Cape Town
Site status: Not listed — confirm with the team
ZA003
Cape Town
Site status: Not listed — confirm with the team
ZA004
Cape Town
Site status: Not listed — confirm with the team
ZA005
Cape Town
Site status: Not listed — confirm with the team
ZA008
Durban
Site status: Not listed — confirm with the team
ZA007
Port Elizabeth
Site status: Not listed — confirm with the team
ZA001
Pretoria
Site status: Not listed — confirm with the team
ZA009
Pretoria
Site status: Not listed — confirm with the team
Sweden · 3 sites
SE001
Falun
Site status: Not listed — confirm with the team
SE002
Stockholm
Site status: Not listed — confirm with the team
SE003
Uppsala
Site status: Not listed — confirm with the team
United States · 22 sites
US004
Los Angeles, California
Site status: Not listed — confirm with the team
US025
Los Angeles, California
Site status: Not listed — confirm with the team
US024
Riverside, California
Site status: Not listed — confirm with the team
US015
San Diego, California
Site status: Not listed — confirm with the team
US008
San Diego, California
Site status: Not listed — confirm with the team
US002
Bradenton, Florida
Site status: Not listed — confirm with the team
US006
Gainesville, Florida
Site status: Not listed — confirm with the team
US016
Jacksonville, Florida
Site status: Not listed — confirm with the team
US020
North Miami, Florida
Site status: Not listed — confirm with the team
US017
Tampa, Florida
Site status: Not listed — confirm with the team
US012
Indianapolis, Indiana
Site status: Not listed — confirm with the team
US021
Roslindale, Massachusetts
Site status: Not listed — confirm with the team
US019
Las Vegas, Nevada
Site status: Not listed — confirm with the team
US007
Nashua, New Hampshire
Site status: Not listed — confirm with the team
US001
The Bronx, New York
Site status: Not listed — confirm with the team
US009
Cincinnati, Ohio
Site status: Not listed — confirm with the team
US005
Dayton, Ohio
Site status: Not listed — confirm with the team
US010
Portland, Oregon
Site status: Not listed — confirm with the team
US014
Norristown, Pennsylvania
Site status: Not listed — confirm with the team
US011
Memphis, Tennessee
Site status: Not listed — confirm with the team
US003
Austin, Texas
Site status: Not listed — confirm with the team
US026
Seattle, Washington
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving Placebo, Brexpiprazole. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by H. Lundbeck A/S, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
